18 research outputs found
Prehospital and intra-hospital time delays in posterior circulation stroke : results from the Austrian Stroke Unit Registry
Therapeutic effect of recombinant tissue-plasminogen activator (rt-PA) is time dependent. There is limited evidence whether localization of stroke within the posterior circulation (PCS) is associated with a treatment delay. We aimed to analyze within a nationwide multicenter cohort whether duration of pre- and intra-hospital patient management differs between patients with PCS and anterior circulation strokes (ACS). We studied onset-to-door-times (ODT) and door-to-needle-times (DNT) of all patients with acute ischemic stroke (IS) enrolled in the Austrian Stroke Unit Registry according to infarct localization. Classification into PCS and ACS was based on clinical presentation applying the criteria used in the Oxfordshire Community Stroke Project. Relationships between ODT, respectively, DNT and explanatory variables were modeled by multivariate linear regression. Between 2003 and 2015, 71010 patients with IS were enrolled, 11,924 with PCS and 59,086 with ACS. Overall, the ODT was significantly longer in PCS: median (IQR): 170 (25th, 75th: 79,420) min versus 110 (60,240); p < 0.001; this finding held true in multivariable analysis. In 10535 rt-PA-treated patients (1022 PCS/9832 ACS), ODT and DNT were significantly longer among those with PCS: ODT: median: 80 min (55,120) versus 72 (50,110), p < 0.001; DNT: 57 (35.90) versus 45 (30.67), p < 0.001. In the multivariate model, PCS was significantly associated with delay in the DNT. In conclusion, in this large nationwide cohort, patient management was significantly slower in PCS as compared to ACS. Increasing awareness about these delays and further elaboration of the underlying causes may translate into higher proportions of patients with PCS receiving rt-PA.(VLID)349737
Recommended from our members
The Thr715Pro Polymorphism of the P-Selectin Gene Is Not Associated With Ischemic Stroke Risk
Background and Purpose—
A Thr>Pro polymorphism at codon 715 in the coding region of the P-selectin gene has recently been described. Individuals carrying the Pro715 allele were reported to have a reduced risk of myocardial infarction. A possible association of this polymorphism with the risk of ischemic stroke is currently under discussion.
Methods—
We investigated the prevalence of the 715 Thr>Pro polymorphism in 450 patients aged younger than 60 years with ischemic stroke or transient ischemic attack and in 450 controls without vascular disease matched for age and gender. We also investigated possible interactions of the polymorphism with other vascular risk factors, stroke severity and stroke etiology.
Results—
The distribution of the two allelic variants of the 715Thr>Pro polymorphism did not differ significantly between patients and control subjects (78% versus 81% for Thr/Thr, 21% versus 18% for Thr/Pro and 1% versus 1% for Pro/Pro in patients and controls, respectively; adjusted odds ratio for carriers of the C allele: 1.0 [0.8 to 1.2;
P
=0.695]). We found no significant interaction of this polymorphism with vascular risk factors, stroke severity, or stroke etiology.
Conclusions—
Our study supports results from previous investigation showing that the 715Thr>Pro polymorphism of the P-selectin gene was not associated with a risk or clinical characteristics of ischemic stroke
Polymorphisms Associated with Both Noncardioembolic Stroke and Coronary Heart Disease: Vienna Stroke Registry
Noncardioembolic stroke and coronary heart disease (CHD) may share genetic predispositions. We tested the hypothesis that genetic variants which are associated with risk of CHD would also be associated with risk of noncardioembolic stroke in 562 cases from the Vienna Stroke Registry and 815 controls. We selected 6 gene variants that had been consistently associated with risk of CHD in 3 studies, including the Atherosclerosis Risk in Communities study, and found that 4 of these gene variants were also associated with risk of noncardioembolic stroke. The odds ratios for noncardioembolic stroke were 1.31 (90% CI 1.07–1.60) for rs3900940 in MYH15, 1.24 (90% CI 1.01–1.5) for rs20455 in KIF6, 1.21 (90% CI 0.99–1.49) for rs1010 in VAMP8, and 1.20 (90% CI 0.95–1.50) for rs10757274 on chromosome 9p21
Demographic and Geographic Vascular Risk Factor Differences in European Young Adults With Ischemic Stroke The 15 Cities Young Stroke Study
Background and Purpose-We compared among young patients with ischemic
stroke the distribution of vascular risk factors among sex, age groups,
and 3 distinct geographic regions in Europe.
Methods-We included patients with first-ever ischemic stroke aged 15 to
49 years from existing hospital-or population-based prospective or
consecutive young stroke registries involving 15 cities in 12 countries.
Geographic regions were defined as northern (Finland, Norway), central
(Austria, Belgium, France, Germany, Hungary, The Netherlands,
Switzerland), and southern (Greece, Italy, Turkey) Europe. Hierarchical
regression models were used for comparisons.
Results-In the study cohort (n=3944), the 3 most frequent risk factors
were current smoking (48.7%), dyslipidemia (45.8%), and hypertension
(35.9%). Compared with central (n=1868; median age, 43 years) and
northern (n=1330; median age, 44 years) European patients, southern
Europeans (n=746; median age, 41 years) were younger. No sex difference
emerged between the regions, male: female ratio being 0.7 in those aged
<34 years and reaching 1.7 in those aged 45 to 49 years. After
accounting for confounders, no risk-factor differences emerged at the
region level. Compared with females, males were older and they more
frequently had dyslipidemia or coronary heart disease, or were smokers,
irrespective of region. In both sexes, prevalence of family history of
stroke, dyslipidemia, smoking, hypertension, diabetes mellitus, coronary
heart disease, peripheral arterial disease, and atrial fibrillation
positively correlated with age across all regions.
Conclusions-Primary preventive strategies for ischemic stroke in young
adults-having high rate of modifiable risk factors-should be targeted
according to sex and age at continental level. (Stroke. 2012;
43:2624-2630.